Corbus Pharmaceuticals(CRBP) - 2025 Q4 - Annual Report

Drug Development and Clinical Trials - Corbus Pharmaceuticals is focused on developing innovative therapies in oncology and obesity, with a pipeline that includes CRB-701 and CRB-913[17]. - CRB-701 is currently in a Phase 1/2 study, with 167 patients enrolled, showing an unconfirmed objective response rate (ORR) of 33.3% for HNSCC at a 2.7 mg/kg dose and 47.6% at a 3.6 mg/kg dose[25][27]. - For cervical cancer patients, CRB-701 demonstrated an ORR of 22.2% at 2.7 mg/kg and 37.5% at 3.6 mg/kg, while mUC patients showed an ORR of 50.0% at 2.7 mg/kg and 55.6% at 3.6 mg/kg[31][34]. - The most common treatment-emergent adverse events (TEAEs) were fatigue (21.6%), alopecia (24.0%), and keratitis (32.3%), with no dose-limiting toxicities reported[40]. - CRB-913, an oral small molecule for obesity treatment, completed a Phase 1a study with no serious treatment-emergent adverse events and no gastrointestinal intolerability reported[49]. - The Phase 1a study for CRB-913 included 64 participants in the single ascending dose (SAD) portion and 48 in the multiple ascending dose (MAD) portion, with a maximum dose of 600 mg/day[48]. - CRB-701 has received fast track designation from the FDA for treating relapsed or refractory metastatic cervical cancer and recurrent or metastatic HNSCC[20]. - The company plans to meet with the FDA in Q1 2026 to discuss clinical data and registrational study protocols for HNSCC and cervical tumors[45]. - CRB-701's pharmacokinetic profile indicates a longer half-life and lower free-MMAE exposure compared to PADCEV® at comparable dose levels[45]. - The company initiated a Phase 1b dose-range finding study ("CANYON-1") in December 2025, involving 240 U.S. subjects randomized into 4 arms over a 12-week treatment period[60]. - The CANYON-1 study is expected to complete in summer 2026, further advancing the development of CRB-913[60]. - The clinical development process includes three phases: Phase 1 focuses on safety with small groups, Phase 2 assesses efficacy in affected patients, and Phase 3 gathers extensive data on effectiveness and safety with several hundred to several thousand subjects[84]. Financial Performance and Funding - As of December 31, 2025, the company had an accumulated deficit of approximately $555.4 million, with net losses of approximately $78.5 million and $40.2 million for the years ended December 31, 2025 and 2024, respectively[134]. - The company held cash, cash equivalents, and investments of approximately $163.3 million as of December 31, 2025, which will fund operations for a limited time[136]. - The company sold an aggregate of 563,504 shares of common stock for net proceeds of approximately $7.0 million under the Open Market Sale Agreement during the year ended December 31, 2025[137]. - On November 3, 2025, the company completed a public offering raising net proceeds of $70.2 million after deducting underwriting discounts and commissions[139]. - The company has never generated any product revenues and expects to incur significant losses for the foreseeable future, indicating a high degree of risk for investors[131]. - The company may need to raise additional capital through private and public equity offerings, debt financings, and strategic collaborations to support its development efforts[140]. - The company expects to continue incurring substantial expenses without corresponding revenues until it can obtain regulatory approval and successfully commercialize its drug candidates[134]. Regulatory Environment - The regulatory approval process for drug candidates requires substantial time and financial resources, with potential delays or rejections impacting commercialization[78]. - The FDA requires a clinical plan submission before trials begin, and can suspend or terminate studies if safety concerns arise[85]. - Post-approval studies, or Phase 4 trials, may be mandated by the FDA to gather additional data on safety and efficacy after initial marketing approval[86]. - Clinical trial results may not fully predict a product's safety and effectiveness, and unforeseen issues can arise that delay commercialization[87]. - The FDA's Special Protocol Assessment allows for agreement on clinical trial design, but the agency retains the right to change its assessment based on new findings[89]. - The FDA may impose conditions on approvals, including risk evaluation strategies, which could restrict marketing and distribution[93]. - The Orphan Drug Act provides potential benefits such as grant funding of up to $400,000 per year for four years for drugs treating rare diseases[97]. - The U.S. Patent Term Restoration Act allows for a patent restoration term of up to five years, but cannot extend beyond a total of 14 years from the product's approval date[105]. - The company must navigate complex regulatory environments in both the U.S. and EU, which include extensive monitoring and compliance requirements post-approval[114][115]. Competition and Market Dynamics - The company faces competition from major pharmaceutical and biotechnology companies, including Novo Nordisk A/S and Pfizer Inc., in the obesity treatment market[77]. - Competition in the biotechnology and pharmaceutical industries is intense, with established competitors potentially making the company's drug candidates obsolete or uneconomical[170]. - Legislative changes, such as the Inflation Reduction Act of 2022, may limit pricing and reimbursement for drug candidates, adversely affecting profitability[176]. - The company's future growth depends on successful market entry and commercialization of drug candidates in non-U.S. markets, which involves additional regulatory and commercial risks[177]. Manufacturing and Supply Chain - The Company relies on third-party contract manufacturing organizations for the supply of drugs for clinical studies, which could impact clinical trial timelines if delays occur[72]. - The company is completely dependent on third parties for manufacturing drug candidates, which could halt or delay commercialization if these parties fail to meet regulatory standards[182]. - Contract manufacturers must comply with current good manufacturing practices (cGMPs), and failure to do so could impact the company's ability to obtain regulatory approval[183]. - The company relies on contract manufacturers for drug production, which are subject to FDA inspections and compliance with cGMPs, posing risks of sanctions and operational disruptions[184]. - There is a risk of supply interruptions if third-party manufacturers face difficulties, which could adversely affect the ability to produce drug candidates[185]. - The company depends on foreign third parties for materials and services in clinical trials, with potential impacts from tariffs and trade restrictions that could increase costs and disrupt supply chains[186]. - Manufacturing costs for drug candidates may exceed expectations, impacting operating results and necessitating process improvements subject to regulatory approval[187]. - Scaling up manufacturing to commercial levels carries risks such as cost overruns and technical problems, which could delay regulatory approval and commercialization[188]. Intellectual Property and Legal Risks - The company faces challenges in protecting intellectual property rights, with potential impacts on competitive advantage and revenue generation[202]. - There is uncertainty regarding the enforceability of existing patents and the potential for third-party challenges to intellectual property rights[203]. - The company relies on trade secrets for technology protection, which are difficult to safeguard and may be compromised[204]. - The company has licensed intellectual property from partners, and failure to comply with obligations could result in loss of rights or damages[207]. - The company is subject to potential claims of patent infringement, which could lead to costly litigation and delays in product commercialization[209]. - The company may face significant litigation costs and distractions from management due to claims related to the use of confidential information or trade secrets[214].